N-Hydroxy-N-1-[4-[4-(4-fluorophenyl)5-(4-pyridyl)-1H-imidazol-2-yl]phenyl]-ethylurea | 172747-45-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: N-Hydroxy-N-1-[4-[4-(4-fluorophenyl)5-(4-pyridyl)-1H-imidazol-2-yl]phenyl]-ethylurea
• 英文别名: N-Hydroxy-N-[1-[4-[4-(4-fluorophenyl)-5-(4-pyridyl)1H-imidazol-2-yl]phenyl]ethyl]urea；1-[1-[4-[4-(4-fluorophenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]phenyl]ethyl]-1-hydroxyurea
• CAS: 172747-45-4
• 化学式: C₂₃H₂₀FN₅O₂
• 分子量: 417.443
• InChiKey: JVMAHSCWJIZBJE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  31
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  108
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  a-Methyl-4-[4-(4-fluorophenyl)-5-(4-pyridyl)imidazol-2-yl]benzyl alcohol 、 N,O-bis-benzyloxycarbonyl-hydroxylamine 在 偶氮二甲酸二乙酯 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 以14%的产率得到N-Hydroxy-N-1-[4-[4-(4-fluorophenyl)5-(4-pyridyl)-1H-imidazol-2-yl]phenyl]-ethylurea
  参考文献：
  名称：

  Imidazole derivatives and their use as cytokine inhibitors

  摘要：

  作为细胞因子抑制剂的2,4,5-三芳基咪唑化合物和组合物，用作细胞因子抑制剂。

  公开号：

  US05686455A1

文献信息

• [EN] IMIDAZOLE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS
  申请人：SMITHKLINE BEECHAM CORPORATION

  公开号：WO1993014081A1

  公开（公告）日：1993-07-22

  (EN) Novel 2,4,5-triarylimidazole compounds and compositions for use in therapy.(FR) Nouveaux composés 2,4,5-triarylimidazole et compositions s'utilisant en thérapie.

  (EN) 新型2,4,5-三芳基咪唑化合物及其在治疗中的应用组合物。 (FR) 新型2,4,5-三芳基咪唑化合物及其在治疗中的应用组合物。
• Novel compounds
  申请人：SmithKline Beecham Corporation

  公开号：US20030064997A1

  公开（公告）日：2003-04-03

  Novel 2,4,5-triaryl imidazole compounds and compositions for use in therapy.

  小说2,4,5-三芳基咪唑化合物及其在治疗中的应用组成物。
• Compounds
  申请人：SmithKline Beecham Corporation

  公开号：US06268370B1

  公开（公告）日：2001-07-31

  Novel 2,4,5-triaryl imidazole compounds and compositions for use in therapy.

  小说2,4,5-三芳基咪唑化合物和治疗用组合物。
• Combination therapy for treating, preventing or managing proliferative disorders and cancers
  申请人：——

  公开号：US20040067953A1

  公开（公告）日：2004-04-08

  The present invention relates to methods and compositions designed for the treatment, management or prevention of cancer. The methods of the invention comprise the administration of an effective amount of one or more inhibitors of JNK in combination with the administration of an effective amount of one or more other agents useful for cancer therapy. The invention also provides pharmaceutical compositions comprising one or more inhibitors of JNK in combination with one or more other agents useful for cancer therapy. In particular, the invention is directed to methods of treatment and prevention of cancer by the administration of an effective amount of one or more inhibitors of JNK in combination with standard and experimental chemotherapies, hormonal therapies, bone marrow transplants, stem cell replacement therapies, biological therapies/immunotherapies and/or radiation therapies for treatment or prevention of cancer. Also included are methods of treatment of cancer by the administration of one or more inhibitors of JNK in combination with surgery, alone or in further combination with standard and experimental chemotherapies, hormonal therapies, bone marrow transplants, stem cell replacement therapies, biological therapies/immunotherapies and/or radiation therapies.

  本发明涉及用于治疗、控制或预防癌症的方法和组合物。本发明的方法包括施用有效量的一种或多种 JNK 抑制剂，并结合施用有效量的一种或多种其他用于癌症治疗的制剂。本发明还提供了药物组合物，其中包含一种或多种 JNK 抑制剂与一种或多种其他有助于癌症治疗的药物。特别是，本发明涉及通过施用有效量的一种或多种JNK抑制剂与标准和实验性化疗、激素疗法、骨髓移植、干细胞替代疗法、生物疗法/免疫疗法和/或放射疗法联合治疗或预防癌症的方法。还包括通过施用一种或多种JNK抑制剂结合手术、单独或进一步结合标准和实验性化疗、激素疗法、骨髓移植、干细胞替代疗法、生物疗法/免疫疗法和/或放射疗法治疗癌症的方法。
• IMIDAZOLE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS
  申请人：SMITHKLINE BEECHAM CORPORATION

  公开号：EP0623126A1

  公开（公告）日：1994-11-09